The European Medicines Agency published a Q&A on 3D-printed (3DP) solid oral dosage forms on 12 March 2026 under reference EMA/CHMP/CVMP/QIG/GMP/QWP/55150/2026. The document is a joint output of the Quality Innovation Group (QIG), CHMP, CVMP, the GMP Inspectors Working Group and the Quality Working Party. It sets quality and GMP expectations for marketed 3D-printed solids in both human and veterinary medicines, with investigational and pharmacy-prepared products scoped separately.

The Q&A explicitly endorses inline process analytical technology - specifically near-infrared and Raman spectroscopy, alongside pressure and balance sensors - as part of the control strategy for personalised small-batch production. EMA frames this within a Quality by Design rationale: where each printed unit can be measured and accepted or rejected in line, real-time release testing principles extend down to the individual dosage unit. The document points operators to the existing EMA guidelines on Real Time Release Testing and Parametric Release rather than creating a parallel regime, and ties analytical procedure development for these inline methods to ICH Q14, in force in the EU since June 2024.

The Q&A lands alongside the QIG’s 2026-2028 rolling work plan, published 5 December 2025, which lists pharmaceutical process models including AI, end-to-end continuous manufacturing and decentralised manufacturing as flagship priorities. A separate Q&A on Decentralised Manufacturing is named as an ongoing deliverable, and the parent Joint CHMP/CVMP Quality Working Party work plan signals coordinated guidance output through 2028.

For operators, the practical change is narrow but precedent-setting. The 2006 PAT reflection paper and the Q8 to Q14 ICH stack covered multivariate analytical procedures and design-space concepts but never addressed personalised 3DP solids. The March 2026 Q&A is the first EMA primary to accept NIR or Raman-driven inline rejection of individual printed units as a substitute for conventional end-product testing in a personalised micro-batch regime. Vendors of inline NIR and Raman platforms targeting compounding and decentralised manufacturing now have an explicit EU regulatory hook to cite, and chemometric model lifecycle expectations carry across from Q14 implementation work already in motion across the bloc.